Skip to content

Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma (METT)

Locations:

National Cancer Center Korea
Ilsan, Gyeonggi-Do, Korea, Republic of, 10408

Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-Do, Korea, Republic of, 13620

Ajou University Hospital
Suwon-si, Gyeonggi-Do, Korea, Republic of, 16499

Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-Do, Korea, Republic of, 58128

Incheon St. Mary’s Hospital
Incheon, Korea, Republic of, 21431

Seoul National University Hospital
Seoul, Korea, Republic of, 03080

Severance Hospital
Seoul, Korea, Republic of, 03722

Konkuk University Hospital
Seoul, Korea, Republic of, 05030

Asan Medical Center
Seoul, Korea, Republic of, 05505

Samsung Medical Center
Seoul, Korea, Republic of, 06351

Seoul St Mary’s Hospital
Seoul, Korea, Republic of, 06591

Saint Vincent’s Hospital, Korea
Suwon-si, Korea, Republic of, 16247

Contacts:

Yong-Kil Hong, MD., PhD.    82-2-2258-2101    hongyk@catholic.ac.kr

Seung Ho Yang, MD., PhD.     82-31-249-8304 72ysh@catholic.ac.kr

Inclusion criteria: 

For those experiencing Recurrence or Progression

Treatment Protocol: 

Patients will take Metformin along with a low dose of Temodar

Link: 

https://clinicaltrials.gov/ct2/show/NCT03243851

Share on facebook
Share on email
Share on twitter
Share on linkedin

More Metformin Trials

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments